We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.8B
AUM Growth
-$295M
Cap. Flow
-$688M
Cap. Flow %
-3.02%
Top 10 Hldgs %
81.57%
Holding
135
New
6
Increased
16
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$58.8M
2
LEGN icon
Legend Biotech
LEGN
+$52.6M
3
HRTX icon
Heron Therapeutics
HRTX
+$34M
4
JBIO
Jade Biosciences
JBIO
+$32.6M
5
APLS
Apellis Pharmaceuticals
APLS
+$30.9M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$611M
2
NVTA
Invitae Corporation
NVTA
+$179M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$33.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$32.4M
5
ALT icon
Altimmune
ALT
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
76
Assembly Biosciences
ASMB
$507M
$8.18M 0.04%
175,718
+47,266
+37% +$2.34M
KRTX
77
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$7.97M 0.04%
69,966
– –
MREO
78
Mereo BioPharma
MREO
$52.1M
$7.8M 0.03%
2,459,399
-4,260,549
-63% -$14.3M
SPRY icon
79
ARS Pharmaceuticals
SPRY
$578M
$7.36M 0.03%
238,095
– –
BLUE
80
DELISTED
bluebird bio
BLUE
$7.26M 0.03%
17,523
– –
RVMD icon
81
Revolution Medicines
RVMD
$39.1B
$7.05M 0.03%
222,222
– –
DNLI icon
82
Denali Therapeutics
DNLI
$3.86B
$6.96M 0.03%
88,738
– –
CHMA
83
DELISTED
Chiasma, Inc. Common Stock
CHMA
$6.72M 0.03%
1,420,740
+678,607
+91% +$2.56M
HOOK
84
DELISTED
HOOKIPA Pharma
HOOK
$6.42M 0.03%
70,048
– –
BNR
85
Burning Rock Biotech
BNR
$93.9M
$6.16M 0.03%
20,913
– –
REPL icon
86
Replimune Group
REPL
$455M
$5.9M 0.03%
153,512
– –
NGM
87
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$5.75M 0.03%
291,801
– –
CABA icon
88
Cabaletta Bio
CABA
$442M
$5.47M 0.02%
636,363
– –
MGNX icon
89
MacroGenics
MGNX
$239M
$5.39M 0.02%
200,679
– –
ORTX
90
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.23M 0.02%
119,200
+45,757
+62% +$2.55M
ALEC icon
91
Alector
ALEC
$172M
$4.98M 0.02%
239,228
– –
NEXI
92
DELISTED
NexImmune, Inc. Common Stock
NEXI
$4.8M 0.02%
11,765
– –
BMEA icon
93
Biomea Fusion
BMEA
$91.1M
$4.59M 0.02%
+294,117
New +$5.19M
GMDA
94
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$3.91M 0.02%
610,626
-426,600
-41% -$2.94M
ITOS
95
DELISTED
iTeos Therapeutics
ITOS
$3.86M 0.02%
150,346
– –
HRMY icon
96
Harmony Biosciences
HRMY
$2.07B
$3.49M 0.02%
123,600
– –
TCDA
97
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.15M 0.01%
729,300
– –
EVFM
98
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$3.05M 0.01%
179,807
– –
AKRO
99
DELISTED
Akero Therapeutics
AKRO
$2.94M 0.01%
118,378
– –
TCRR
100
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.9M 0.01%
176,461
– –
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Baker Bros. Advisors held 135 positions worth $22.8B, down 1.3% from $23.1B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors withdrew a net $688M in Q2 2021, closing 15 positions and reducing 10 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $611M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Verve Therapeutics worth $85.3M.

  • Baker Bros. Advisors's largest Q2 2021 buy was Verve Therapeutics: 1,416,530 shares worth $85.3M.
  • Baker Bros. Advisors added most to Legend Biotech in Q2 2021, an estimated $52.6M increase.
  • Baker Bros. Advisors's biggest Q2 2021 reduction was Invitae Corporation, cutting an estimated $179M.
  • Baker Bros. Advisors fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $611M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $22.8B portfolio in Q2 2021.
  • Baker Bros. Advisors opened 6 new positions and closed 15 in Q2 2021.
  • Baker Bros. Advisors's portfolio value fell 1.3% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.